Burosumab for Tumor‐Induced Osteomalacia: Not Enough of a Good Thing-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Burosumab for Tumor‐Induced Osteomalacia: Not Enough of a Good Thing

Published:2021-05-05 Issue:12 Volume:36 Page:2453-2454
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J of Bone & Mineral Res

Author:

Hartley Iris R¹^ORCID,Collins Michael T¹^ORCID

Affiliation:

1. National Institute of Dental and Craniofacial Research National Institutes of Health Bethesda MD USA

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.4318

Reference4 articles.

1. Burosumab for the Treatment of Tumor‐Induced Osteomalacia

2. Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia

3. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

4. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-Induced Osteomalacia due to Sarcomatoid Non–Small Cell Lung Carcinoma Confounded by Drug-Induced Fanconi Syndrome;JCEM Case Reports;2024-05-24

2. Preoperative evaluation and orthopedic surgical strategies for tumor-induced osteomalacia;Journal of Bone Oncology;2024-04

3. Burosumab: Current status and future prospects;Best Practice & Research Clinical Endocrinology & Metabolism;2023-09

4. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report;Frontiers in Endocrinology;2022-12-02

5. Appropriate dosing of burosumab in tumor-induced osteomalacia;Osteoporosis International;2022-12-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3